Lisata Therapeutics (Lisata Therapeutics) Net Change in Cash

: $-9.56 Mil (TTM As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Lisata Therapeutics's Net Change in Cash for the three months ended in Dec. 2023 was $-9.84 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.56 Mil.

Lisata Therapeutics Net Change in Cash Historical Data

The historical data trend for Lisata Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

3.73

2.48

8.14

7.51

-9.56

Lisata Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															0.65	-4.00	-4.47	8.74	-9.84

Lisata Therapeutics Net Change in Cash Calculation

Lisata Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-20.032	+	10.102	+	0.385	+	-0.016
	=	-9.56

Lisata Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -4.069 + -5.714 + 0.024 + -0.076

= -9.84

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Lisata Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics (Lisata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Net Change in Cash

Comparable Companies

ABIO SNSE IGC FBRX MEIP GDTC NRSN APRE ONCT SLGL OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX

Traded in Other Exchanges

N/A

Address

110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website

https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Executives

David W. Slack director, officer: President & CBO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920

Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008

Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568

Erkki Ruoslahti director P.O. BOX 544, BUELLTON CA 93427

Steven S Myers director 4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660

Kristen K Buck officer: EVP, R&D and CMO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920

Todd C Girolamo officer: CLO, SVP of Corp Dev 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920

Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560

Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540

Cynthia Schwalm director C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709

David J Mazzo director, officer: Chief Executive Officer 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920

Joseph Talamo officer: SVP and CFO CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573

Douglas W Losordo officer: See Remarks 13 FOX MEADOW RD, SCARSDALE NY 10583

Anford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117

Health Sanford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117

Lisata Therapeutics (Lisata Therapeutics) Headlines

From GuruFocus

Lisata Therapeutics Announces Participation in Upcoming Conferences in February
By Stock market mentor Stock market mentor • 02-01-2023

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANT
By PRNewswire PRNewswire • 08-04-2022

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
By Marketwired • 10-24-2023

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
By Marketwired • 11-02-2023

Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
By sperokesalga sperokesalga • 04-20-2023

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1
By sperokesalga sperokesalga • 05-24-2023

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
By sperokesalga sperokesalga • 05-09-2023

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer�
By Marketwired • 10-17-2023

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
By sperokesalga sperokesalga • 03-30-2023

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
By Marketwired • 08-07-2023

David W. Slack	director, officer: President & CBO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti	director	P.O. BOX 544, BUELLTON CA 93427
Steven S Myers	director	4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck	officer: EVP, R&D and CMO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo	officer: CLO, SVP of Corp Dev	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson	director	OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo	director, officer: Chief Executive Officer	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo	officer: SVP and CFO	CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo	officer: See Remarks	13 FOX MEADOW RD, SCARSDALE NY 10583
Anford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117